Even though about half of the patients experienced a flare of their rheumatoid arthritis (RA), cancer therapy with immune checkpoint inhibitors (ICI) can be continued in most of the cases . Results indicate that rates for serious immune-related adverse events are comparable to those for patients lacking autoimmune disease.
Having comorbidity of autoimmune disease generally leads to the exclusion of oncologic trials with ICI, as there are worries about more immune-related adverse events (irAEs) . “However, patients with autoimmune diseases have the potential to benefit from the use of these therapies,” commented Dr Sabina Sandigursky (New York University Langone Medical Center, USA).
The reported study investigated 84 patients with known autoimmunity who had been treated with anti-CTLA-4 and PD-1 for their cancer from 2011-2018. There were 22 patients of this group who suffered from RA. The majority was female (73%), median age was 67. When sta...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Fibromyalgia Patients Often Experienced Abuse in Childhood Next Article
Depression Closely Related to Fatigue in SLE Patients »
Table of Contents: ACR 2019
Spotlight on Rheumatoid Arthritis
What is Hot in Systemic Lupus Erythematosus
Spondyloarthritis – the Beat Goes On
Osteoarthritis – State-of-the-Art
Reproductive Issues in Rheumatic Disease
Vasculitis – Novel Treatment Modalities
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.